Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects

Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeuti...

Full description

Bibliographic Details
Main Authors:	Antoni Torres, Anna Motos, Denise Battaglini, Gianluigi Li Bassi
Format:	Article
Language:	English
Published:	BMC 2018-12-01
Series:	Critical Care
Subjects:	Pseudomonas aeruginosa Amikacin Ventilator-associated pneumonia Gram-negative bacteria
Online Access:	http://link.springer.com/article/10.1186/s13054-018-1958-4

id	doaj-f67bf3dbc05f48c084cbe29fdc19aaee
record_format	Article
spelling	doaj-f67bf3dbc05f48c084cbe29fdc19aaee2020-11-25T01:52:35ZengBMCCritical Care1364-85352018-12-012211610.1186/s13054-018-1958-4Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospectsAntoni Torres0Anna Motos1Denise Battaglini2Gianluigi Li Bassi3Department of Pulmonary and Critical Care Medicine, Hospital ClinicDepartment of Pulmonary and Critical Care Medicine, Hospital ClinicDepartment of Pulmonary and Critical Care Medicine, Hospital ClinicDepartment of Pulmonary and Critical Care Medicine, Hospital ClinicAbstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials.http://link.springer.com/article/10.1186/s13054-018-1958-4Pseudomonas aeruginosaAmikacinVentilator-associated pneumoniaGram-negative bacteria
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Antoni Torres Anna Motos Denise Battaglini Gianluigi Li Bassi
spellingShingle	Antoni Torres Anna Motos Denise Battaglini Gianluigi Li Bassi Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects Critical Care Pseudomonas aeruginosa Amikacin Ventilator-associated pneumonia Gram-negative bacteria
author_facet	Antoni Torres Anna Motos Denise Battaglini Gianluigi Li Bassi
author_sort	Antoni Torres
title	Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects
title_short	Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects
title_full	Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects
title_fullStr	Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects
title_full_unstemmed	Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects
title_sort	inhaled amikacin for severe gram-negative pulmonary infections in the intensive care unit: current status and future prospects
publisher	BMC
series	Critical Care
issn	1364-8535
publishDate	2018-12-01
description	Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials.
topic	Pseudomonas aeruginosa Amikacin Ventilator-associated pneumonia Gram-negative bacteria
url	http://link.springer.com/article/10.1186/s13054-018-1958-4
work_keys_str_mv	AT antonitorres inhaledamikacinforseveregramnegativepulmonaryinfectionsintheintensivecareunitcurrentstatusandfutureprospects AT annamotos inhaledamikacinforseveregramnegativepulmonaryinfectionsintheintensivecareunitcurrentstatusandfutureprospects AT denisebattaglini inhaledamikacinforseveregramnegativepulmonaryinfectionsintheintensivecareunitcurrentstatusandfutureprospects AT gianluigilibassi inhaledamikacinforseveregramnegativepulmonaryinfectionsintheintensivecareunitcurrentstatusandfutureprospects
_version_	1724994360373673984

Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects

Similar Items